Key result
Carotid stenosis linked to ~39% lower cerebrovascular reserve on acetazolamide TCD testing.
Why the study?
The time course of the acetazolamide effect on cerebrovascular reserve in patients with extracranial carotid artery disease was not fully characterized by standard two-point TCD measurements.
Does continuous TCD monitoring of the acetazolamide effect improve the detection of impaired cerebrovascular reserve compared to standard two-point measurement in patients with carotid artery disease?
Observational (n=69)
Does continuous TCD monitoring of the acetazolamide effect improve the detection of impaired cerebrovascular reserve compared to standard two-point measurement in patients with carotid artery disease?
Continuous TCD monitoring of the acetazolamide effect provides additional information on cerebrovascular reserve and improves the detection of impairment in patients with carotid artery disease compared to standard two-point measurement.
Answers are grounded in this paper and cite their sources.
Continuous TCD monitoring may detect more impaired cerebrovascular reserve than standard two-point testing; leaves open whether it refines risk stratification in carotid disease.
The acetazolamide test of cerebrovascular reserve is performed as a two-point transcranial Doppler (TCD) measurement of the flow velocity in the middle cerebral artery (MCA) before and 15 to 20 minutes after injection of the carbonic anhydrase inhibitor. The time course was evaluated by bilateral TCD monitoring over 45 minutes in 51 patients with extracranial carotid artery disease. Twenty-nine patients in Group 1 showed a unilateral and 22 patients in Group 2, a bilateral stenosis of the internal carotid artery (ICA). Thirty-one normal hemispheres in 18 normal subjects provided baseline control values. The most useful parameter for the description of the time course was the integral of the mean flow velocity. In both groups integral of the mean flow velocity was significantly reduced compared to that in normal persons (Group 1: 587.2 +/- 538.3 cm, p < 0.01; Group 2: 728.9 +/- 397.1 cm, p < 0.01; normal persons: 967.8 +/- 350.0 cm). The maximal increase of mean flow velocity in a two-point measurement also was significantly lower in the patient groups, but did not reach the same level of significance in Group 2 (Group 1: 19.6 +/- 12.3 cm/sec, p < 0.01; Group 2: 24.2 +/- 10.4 cm/sec, p < 0.05). Thirty-four of 73 hemispheres had reduced integral of the mean flow velocity, but only 29 had a reduced maximal increase. These data indicate that continuous monitoring and evaluation of the time course of the acetazolamide effect provide additional information on cerebrovascular reserve and help to detect an increased number of patients with impaired cerebrovascular reserve.
No takes yet. Share an insight, caveat, or question.
Stoll et al. (1996) conducted an observational in Extracranial carotid artery disease (n=69). Acetazolamide test vs. Normal subjects was evaluated on Integral of the mean flow velocity (p=<0.01). Acetazolamide testing showed a reduced integral of mean flow velocity in patients with unilateral and bilateral carotid stenosis versus normal subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: